COLONTOWN is supported by the nonprofit PALTOWN, an organization offering community, training, and disease education for patients and caregivers. Check out the News on PALTOWN’s site for the latest in all our programs, and meet some of our incredible community members as they present at research conferences, create new resources, and provide support for their COLONTOWN neighbors!
June 18, 2021: Announcing our third virtual training Workshop! Our popular Empowered Patient Leaders program is back for Summer 2021. We invite COLONTOWN members interested in stepping up to help manage our community to apply online.
January 21, 2021: Two new initiatives launch! The Second Opinion Project, supporting stage iv patients seeking second opinions, and COLONTOWN Junior, a community for families impacted by pediatric colorectal cancer.
December 10, 2020: COLONTOWN University is now open to all colorectal cancer patients and caregivers. We invite you to join this multimedia educational resource, offering Clinical Trials and Diagnostic and Testing Surveillance Learning Centers, and a Lecture Hall with videos from CRC experts.
July 16, 2019: COLONTOWN founder Erika Brown has published a new editorial describing her vision for patient navigators to help increase participation in cancer clinical trials. In COLONTOWN, this vision is becoming a reality. COLONTOWN’s 140 “neighborhoods” include 9 focused on clinical trials, all led by patient volunteers who work to bring accurate information and education about trial options to the nearly 1500 members of these groups. The PALTOWN Development Foundation, which supports COLONTOWN, has launched a new initiative to train our clinical trials patient navigators, as part of our commitment to developing patient leaders and enabling patients and caregivers to become active participants in care decisions.
Bloomberg Radio: “Markets” Interview with Tom Marsilje
In this April 3, 2017 interview by Carol Massar, COLONTOWN’s Dr. Tom Marsilje explains how members of the Clinic neighborhood are interacting with researchers and learning both about the science behind new therapies and available trials currently recruiting.